bodyType

customContents

entityId

entityUuid

articlePageQuery

filter

article

articleBaseAdvertisingInfoArticle

articleListArticle

articleSeoArticle

hooksArticleAcknowledgementGateOverlayArticle

hooksTrackPageViewArticle

hooksContentInterestArticle

articleLinkingDataContent

hooksAmpRedirectArticle

articleSchemaContent

liveArticle

advertZone

sentiment

contentLock

topics

types

sections

paywallTypes

createdDate

publishedDate

sponsorType

urlAlias

moreOnThisArticles

commentCount

authorLocations

authors

corrections

displaySlideShow

multimediaEmbed

printHeadline

seriesContainer

articleSpeeches

socialHeadline

headline

images

flag

firstTopic

glossary

flattenTypeIds

image

relatedLinks

relatedNewsletters

__typename

sponsor

pdfFiles

seriesReverseOrder

series

disableOffPlatformContent

published

updatedDate

summary

subHeadline

body

keywords

readingTime

customTimezone

liveContents

Reuters

A trial of Pfizer’s experimental antiviral pill for Covid-19 was stopped early after the drug was shown to cut by 89 per cent the chances of hospitalisation or death for adults at risk of developing severe disease, the company said on Friday.
The results appear to surpass those seen with Merck’s pill, molnupiravir, which was shown last month to halve the likelihood of dying or being hospitalised for Covid-19 patients also at high risk of serious illness.
Full trial data is not yet available from either company.
Pfizer shares surged 13 per cent to US$49.47, while those of Merck fell 6 per cent to US$84.69.
Pfizer said it plans to submit interim trial results for its pill, which is given in combination with an older antiviral called ritonavir, to the US Food and Drug Administration as part of the emergency use application it opened in October.
Britain is first to approve Merck’s Covid-19 pill molnupiravir
The combination treatment, which will have the brand name Paxlovid, consists of three pills given twice daily.
The planned analysis of 1,219 patients in Pfizer’s study looked at hospitalisation or deaths among people diagnosed with mild to moderate Covid-19 with at least one risk factor for developing severe disease, such as obesity or older age.
It found that 0.8 per cent of those given Pfizer’s drug within three days of symptom onset were hospitalised and none had died by 28 days after treatment. That compared with a hospitalisation rate of 7 per cent for placebo patients. There were also seven deaths in the placebo group.
Rates were similar for patients treated within five days of symptoms – 1 per cent of the treatment group was hospitalised, compared with 6.7 per cent for the placebo group, which included 10 deaths.


Antivirals need to be given as early as possible, before an infection takes hold, to be most effective. Merck tested its drug within five days of symptom onset.
“We saw that we did have high efficacy, even if it was five days after a patient has been treated … people might wait a couple of days before getting a test or something, and this means that we have time to treat people and really provide a benefit from a public health perspective,” Annaliesa Anderson, head of the Pfizer programme, said.
The company did not detail side effects of the treatment, but said adverse events happened in about 20 per cent of both treatment and placebo patients.
Europe could see another half a million Covid-19 deaths by February: WHO
“These data suggest that our oral antiviral candidate, if approved by regulatory authorities, has the potential to save patients’ lives, reduce the severity of Covid-19 infections, and eliminate up to nine out of 10 hospitalisation,” Pfizer Chief Executive Albert Bourla said in a statement.
Pfizer said it was currently expecting to produce more than 180,000 packs by the end of 2021 and at least 50 million packs by the end of 2022, of which 21 million would be produced in the first half.
“We are currently bringing on additional capacity and ramping up further and we look forward to updating these numbers in the coming weeks,” the company said.


Hong Kong’s Peninsula Hotels sees ‘bleisure’ boom after pandemic curbs, CEO says

US could require US$15,000 bonds for some tourist, business visas

China’s Shenzhen, Guangzhou airports hit record highs, surpass pre-Covid passenger levels

Landmark US Chinatown survived Covid, anti-Asian violence – but tariffs pose new threat

Coronavirus pandemic

Pfizer says Covid-19 pill Paxlovid cuts hospitalisation and deaths by 89 per cent

Pfizer said it plans to submit interim trial results for its pill to the US FDA for emergency use authorisation. Photo: AP

Merck says experimental coronavirus pill cuts deaths and hospitalisations by half

An independent group of medical experts monitoring the Merck trial recommended stopping it early because the interim results were so strong. Photo: Merck & Co. via AP

An antiviral pill, molnupiravir, is being co-developed by Merck & Co. and Ridgeback Biotherapeutics and tested in phase 3 clinical trials to treat and prevent early covid infections. Results are expected within months. (Merck & Co./TNS)

(FILES) In this file photo taken on October 2, 2013, Pharmaceutical company Merck employees walk past a Merck sign in front of the company's building in Summit, New Jersey. - Merck said on October 1, 2021, it will seek authorization in the US for an oral drug for Covid-19, after the pill showed "compelling results" in a clinical trial. The experimental drug, molnupiravir, significantly reduced the risk of hospitalization or death when administered to high-risk patients early in the disease, Merck and its partner Ridgeback Biotherapeutics said in a statement. (Photo by Kena Betancur / GETTY IMAGES NORTH AMERICA / AFP)

Coronavirus: Merck says deal with Singapore signed; South Korea soon to inoculate pregnant women

Merck is seeking US FDA approval for its antiviral pill. Photo: Merck & Co/TNS

FILE PHOTO: An experimental COVID-19 treatment pill called molnupiravir being developed by Merck & Co Inc and Ridgeback Biotherapeutics LP, is seen in this undated handout photo released by Merck & Co Inc and obtained by Reuters May 17, 2021. Merck & Co Inc/Handout via REUTERS ATTENTION EDITORS - THIS IMAGE HAS BEEN SUPPLIED BY A THIRD PARTY. MANDATORY CREDIT. THIS IMAGE WAS PROCESSED BY REUTERS TO ENHANCE QUALITY, AN UNPROCESSED VERSION HAS BEEN PROVIDED SEPARATELY./File Photo

A person in protective face mask walks along the harbour waterfront across from the Sydney Opera House during a lockdown to curb the spread of coronavirus disease (COVID-19) outbreak in Sydney, Australia, October 6, 2021. REUTERS/Loren Elliott

News

World

United States & Canada

Coronavirus

Health & Medicine

The company will submit the data to the US Food and Drug Administration for emergency use authorisation
Pfizer said it aims to produce more than 180,000 packs by the end of 2021


The company will submit the data to the US Food and Drug Administration for emergency use authorisation.


Coronavirus pandemic: All stories

Medicine

Pfizer

Pfizer says Covid-19 pill Paxlovid cuts hospitalisation and deaths by 89 per cent

.css-1mniedq{color:inherit;font-weight:inherit;font-size:inherit;font-family:inherit;line-height:inherit;}The company will submit the data to the US Food and Drug Administration for emergency use authorisation Pfizer said it aims to produce more than 180,000 packs by the end of 2021

The company will submit the data to the US Food and Drug Administration for emergency use authorisation

Pfizer said it aims to produce more than 180,000 packs by the end of 2021